Cardio

The CATANIA™ Coronary Stent System with NanoThin Polyzene®-F offers sustained benefit in the treatment of de novo coronary lesions and maximizes endothelialization, while reducing restenosis, thrombogenicity, and the need for long-term dual-antiplatelet therapy.

Edwards Lifesciences Corporation, the world leader in the science of heart valves, announced that the District Court of Düsseldorf, Germany, today determined that it does not infringe on Cook Inc.’s German transcatheter valve patent.

A Cheshire based medical company Dot Medical, is the only UK Company to offer a unique life saving wearable ‘vest’ that monitors, detects and shocks people having a heart attack.

Invatec, a comprehensive innovator of interventional products, announced CE-certification of a new coronary balloon, the IN.PACT™ Falcon paclitaxel-eluting PTCA balloon catheter.

St. Jude Medical, Inc. announced U.S. Food and Drug Administration approval of the newest version of the Merlin.net™ Patient Care Network, a secure, Internet-based remote care system for patients with implanted medical devices.

Edwards Lifesciences Corporation, the world leader in the science of heart valves, today announced completion of enrollment in the 350-patient non-surgical study arm of its U.S. pivotal trial — known as the PARTNER Trial — for the Edwards SAPIEN transcatheter aortic heart valve.

Flexible Stenting Solutions Inc. has submitted an Investigational Device Exemption application to the FDA for its FlexStent® Femoropopliteal SE Stent System for the treatment of peripheral artery disease in the superficial femoral and popliteal arteries.

LUMEDX Corporation & Mennen Medical® announced today the signing of a strategic partnership agreement to provide a total, integrated cath lab data solution and seamless stream of hemodynamic cardiovascular patient data to their customers.

Cordis Corporation, a worldwide leader in the field of interventional cardiology, announced plans today to launch a global, head-to-head, randomized clinical trial called NEVO II which will compare the NEVO™ Sirolimus-eluting Coronary Stent to the XIENCE V™ Everolimus-eluting Coronary Stent.

Medtronic said Friday that at least 13 people might have died in connection with a heart device that it recalled in 2007 but was still in widespread use.

Medical device pioneer Stentys announced today that it has extended its ‘self-expanding’ and ‘disconnectable’ technology platform to include a second major indication—acute myocardial infarction.

St. Jude Medical, Inc. today announced European CE Mark approval of its Genesis® neurostimulation system for managing a form of chest pain known as chronic angina pectoris, or chronic angina.

Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced that the first series of patients have been successfully treated with the MitraClip® system at the Cardiocentro Ticino in Lugano, Switzerland.

VOYAGER™ NC Coronary Balloon Catheter is the latest Innovation in Balloon Technology, Designed to Optimize Treatment of Patients with Coronary Artery Disease

SyntheMed, Inc., a biomaterials company engaged in the development and commercialization of anti-adhesion products, today announced that the U.S. Food and Drug Administration has approved the Pre-market Approval application for REPEL-CV® Adhesion Barrier for use in pediatric cardiac surgery patients.

Stereotaxis, Inc. announced today that clinicians at two centers in the United States have performed successful cardiac ablation procedures with the NAVISTAR® RMT THERMOCOOL® catheter since the announcement of its approval by the U.S. Food and Drug Administration on February 26.